Responding to rising mpox cases in Africa, the World Health Organization declared a public health emergency of international ...

The AstraZeneca PLC ADR AZN inched 0.06% higher to $78.58 Wednesday, on what proved to be an all-around dismal trading ...

More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.

JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the ...

EGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...

The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...

Shares of AstraZeneca PLC AZN inched down 0.94% to £118.56 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100 Index UKX falling 0.68% to 8,253 ...

Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.

AstraZeneca (AZN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...